Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf mouse model.

Proc Natl Acad Sci U S A 2017 03 6;114(12):3151-3156. Epub 2017 Mar 6.

Oncology Disease Area, Novartis Institutes for BioMedical Research, 4056 Basel, Switzerland.

Inhibitors of double minute 2 protein (MDM2)-tumor protein 53 (TP53) interaction are predicted to be effective in tumors in which the gene is wild type, by preventing TP53 protein degradation. One such setting is represented by the frequent deletion in human cancer that, through inactivation of , activates MDM2 protein, which in turn degrades TP53 tumor suppressor. Here we used piggyBac (PB) transposon insertional mutagenesis to anticipate resistance mechanisms occurring during treatment with the MDM2-TP53 inhibitor HDM201. Constitutive PB mutagenesis in mice provided a collection of spontaneous tumors with characterized insertional genetic landscapes. Tumors were allografted in large cohorts of mice to assess the pharmacologic effects of HDM201. Sixteen out of 21 allograft models were sensitive to HDM201 but ultimately relapsed under treatment. A comparison of tumors with acquired resistance to HDM201 and untreated tumors identified 87 genes that were differentially and significantly targeted by the PB transposon. Resistant tumors displayed a complex clonality pattern suggesting the emergence of several resistant subclones. Among the most frequent alterations conferring resistance, we observed somatic and insertional loss-of-function mutations in transformation-related protein 53 () in 54% of tumors and transposon-mediated gain-of-function alterations in B-cell lymphoma-extra large (), , and two family members, resulting in expression of the TP53 dominant negative truncations and Enhanced BCL-xL and MDM4 protein expression was confirmed in resistant tumors, as well as in HDM201-resistant patient-derived tumor xenografts. Interestingly, concomitant inhibition of MDM2 and BCL-xL demonstrated significant synergy in p53 wild-type cell lines in vitro. Collectively, our findings identify several potential mechanisms by which wild-type tumors may escape MDM2-targeted therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1620262114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5373361PMC
March 2017
157 Reads

Publication Analysis

Top Keywords

tumors
9
resistant tumors
8
piggybac transposon
8
resistance mechanisms
8
protein
6
transposon resistant
4
tumors displayed
4
targeted transposon
4
displayed complex
4
genes differentially
4
hdm201 untreated
4
resistance hdm201
4
untreated tumors
4
tumors identified
4
identified genes
4
differentially targeted
4
clonality pattern
4
conferring resistance
4
alterations conferring
4
resistance observed
4

References

(Supplied by CrossRef)
Database of p53 gene somatic mutations in human tumors and cell lines
Hollstein et al.
Nucleic Acids Res 1994
The p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas et al.
Biochim Biophys Acta 1998
Small molecule HDM2 inhibitor HDM201
Hofmann et al.
Proceedings of the 107th Annual Meeting of the American Association for Cancer Research. Cancer Res 2016

Similar Publications